ArticleCell division2026
The TMPO-AS1/hsa-let-7b-5p regulatory axis shapes transcriptional heterogeneity and immune landscape in lung adenocarcinoma.
Article in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a highly heterogeneous malignancy with poor clinical outcomes, underscoring the urgent need for robust prognostic biomarkers and therapeutically tractable regulatory molecules. Long non-coding RNAs (lncRNAs) have emerged as key modulators of tumor progression and immune regulation; however, the prognostic and functional significance of TMPO-AS1 in LUAD remains largely unexplored.
methodsFirstly, the top upregulated lncRNAs in LUAD were identified using the lnc2cancer3.0 database, and their prognostic significance was evaluated with the Kaplan-Meier Plotter. Differential expression of the selected lncRNA candidate was validated using TCGA-based platforms, including UALCAN, ENCORI and R-based statistical packages. TMPO-AS1-associated miRNAs were then predicted using the miRNet database, and their expression correlations, prognostic relevance, and differential expressions were assessed using the ENCORI, KM Plotter databases and R-based packages, respectively. A miRNA-centered heterogeneous gene model was constructed using the CancerMIRNome database, and gene-miRNA correlations were validated via ENCORI, followed by their survival analysis using the KM Plotter. Finally, immune cell infiltration associated with the identified genes was analyzed using the GSCA dataset.
resultsTMPO-AS1 was found to be significantly overexpressed in LUAD patients (HR = 2.16). The correlation analysis revealed hsa-let-7b-5p was significantly and negatively correlated with TMPO-AS1, and its overexpression was also linked with better prognosis. Survival analysis selectively highlighted TGFBR3, RNF144B, CD59, and MAT2B as the most significant positively associated genes, while AURKA and KIFC1 emerged as the most significant negatively associated genes. Immune infiltration analysis demonstrated that the miRNA-positively associated genes were negatively correlated with nTreg cells and positively correlated with NKT cells, whereas the miRNA-negatively associated genes showed an inverse correlation pattern.
conclusionThe study concludes that TMPO-AS1 is overexpressed in cases of LUAD, highlighting its potential as a molecular classifier for LUAD and a prognostic biomarker associated with poor clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.